{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-047487","form_type":"8-K","ticker":"ADMA","cik":"0001368514","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2024-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.270037+00:00","generated_at":"2026-05-29T20:28:41.679921+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"ADMA Biologics board member Bryant Fong resigns; committee chairs reassigned","bullets":["Bryant Fong resigned from board effective Nov 19, 2024 to focus on other roles; no disagreements.","Young T. Kwon appointed Chairman of Audit Committee and designated audit committee financial expert.","Steven A. Elms added to Audit Committee.","Alison C. Finger added to Governance and Nominations Committee and Compensation Committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-047487","json":"https://secwatch.observer/filing/0001140361-24-047487.json","markdown":"https://secwatch.observer/filing/0001140361-24-047487.md","text":"https://secwatch.observer/filing/0001140361-24-047487.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124047487/0001140361-24-047487-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124047487/ef20038782_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T20:28:41.679921+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1c94ec53f0","claim":"Bryant E. Fong resigned as member of the Board of Directors at ADMA BIOLOGICS, INC..","evidence_excerpt":"On November 19, 2024, Bryant E. Fong notified ADMA Biologics, Inc. (the “Company”) that he resigned, effective immediately, as a member of the Company’s Board of Directors (the “Board”) and any committees of the Board in order to devote more time to his roles as Managing Director of Biomark Capital Fund and as Partner and Co-Portfolio Manager of Stonepine Capital Management.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124047487/0001140361-24-047487-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"member of the Board of Directors"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}